Glycemic Testing: Fasting Plasma Glucose, HbA1c Pitfalls, and Oral Glucose Tolerance Test (OGTT)

Glucose homeostasis is tightly regulated by a dynamic equilibrium between pancreatic beta-cell insulin secretion and hepatic/peripheral insulin sensitivity. Glycemic biomarkers capture different physiological windows of carbohydrate metabolism:

1. Fasting Plasma Glucose (FPG): Reflects basal hepatic gluconeogenesis and glycogenolysis during the post-absorptive state (8–12 hours fast), governed primarily by basal insulin secretion and hepatic insulin sensitivity.
2. Oral Glucose Tolerance Test (OGTT): Measures dynamic whole-body glucose disposal in response to a standardized physiological carbohydrate challenge (75 grams of anhydrous glucose dissolved in water). Evaluates acute first-phase and second-phase insulin secretion and peripheral skeletal muscle insulin sensitivity.
3. Glycated Hemoglobin ($HbA_{1c}$): Formed by a slow, non-enzymatic, irreversible ketoamine condensation (Amadori rearrangement) between ambient plasma glucose and the N-terminal valine residue of the hemoglobin β-chain inside circulating erythrocytes. Because the average human red blood cell circulates for 120 days, HbA₁c integrates and reflects mean ambient glycemia over the preceding 2 to 3 months, weighted heavily toward the most recent 30 days (50% contributed by the preceding month, 25% by months 2, and 25% by months 3–4).

Automated HbA₁c measurement is standardized globally by the National Glycohemoglobin Standardization Program (NGSP) and the International Federation of Clinical Chemistry (IFCC).

Pre-analytic handling errors are the single greatest cause of spurious plasma glucose results:

Note: In the absence of unequivocal symptomatic hyperglycemia (polyuria, polydipsia, weight loss with random glucose $\ge 200\text{ mg/dL}$), diagnosis requires two abnormal test results from the same sample or two separate test occasions.

Diagnosis is confirmed if $\ge 1$ value equals or exceeds:

• Fasting: ≥ 92 mg/dL (5.1 mmol/L)
• 1-Hour: ≥ 180 mg/dL (10.0 mmol/L)
• 2-Hour: ≥ 153 mg/dL (8.5 mmol/L)

1. Screening for Diabetes and Prediabetes: All asymptomatic adults aged ≥ 35 years, or adults of any age with overweight/obesity (BMI ≥ 25 kg/m², or ≥ 23 kg/m² in Asian Americans) plus ≥ 1 risk factor (first-degree relative with diabetes, high-risk ethnicity, history of CVD, hypertension, HDL < 35 mg/dL, triglycerides > 250 mg/dL, PCOS).
2. Evaluation of Hyperglycemic Symptoms: Polyuria, polydipsia, polyphagia, blurred vision, recurrent vulvovaginal candidiasis, unexplained weight loss.
3. Monitoring Chronic Glycemic Control: Evaluating efficacy of dietary, oral antihyperglycemic, or insulin therapy in diagnosed diabetes (performed every 3 months in uncontrolled patients, every 6 months in stable patients).
4. Obstetric Screening: Universal screening for GDM at 24 to 28 weeks of gestation.
5. Investigation of Hypoglycemia: Whipple triad (symptoms of hypoglycemia, documented plasma glucose < 55 mg/dL, relief of symptoms upon glucose administration).

Step 1: Check Presence of Classic Symptoms
   ├─ Classic polyuria, polydipsia, weight loss + Random Glucose >= 200 mg/dL ──> Confirms Diabetes (No repeat needed)
   └─ Asymptomatic patient ────────────────────────────────────────────────────> Proceed to Step 2

Step 2: Check Fasting Glucose and HbA1c Results
   ├─ FPG >= 126 mg/dL OR HbA1c >= 6.5% ──> Requires repeat confirmation on a separate day
   ├─ FPG 100-125 OR HbA1c 5.7-6.4% ──────> Diagnoses Prediabetes (Impaired Fasting Glucose)
   └─ FPG < 100 AND HbA1c < 5.7% ──────────> Normal Euglycemia

Step 3: Screen for HbA1c Discrepancies and Red Cell Turnover
   ├─ Is the patient anemic, on dialysis, pregnant, or hemolytic?
   │     └─ YES ──> HbA1c is UNRELIABLE. Use Fasting Glucose, OGTT, or Fructosamine
   └─ NO ───────> HbA1c is valid and reflects 90-day mean glycemia

Step 4: Resolve Discordant Results (e.g. FPG normal, HbA1c diabetic)
   ├─ If two different tests are discordant, repeat the test that is ABOVE the diagnostic threshold
   └─ If confirmed, the patient is diagnosed with diabetes based on the abnormal test

• High FPG with Normal $HbA_{1c}$: Early acute onset diabetes (e.g., rapid-onset autoimmune Type 1 diabetes in youth), acute steroid-induced hyperglycemia, or conditions with accelerated red cell turnover falsely lowering HbA₁c.
• Normal FPG with High $HbA_{1c}$: Isolated postprandial hyperglycemia (prominent in early Type 2 diabetes where fasting hepatic glucose output is controlled but postprandial muscle uptake is defective), or iron deficiency anemia falsely elevating HbA₁c.

• IFG ($\text{FPG } 100\text{–}125\text{ mg/dL}$) primarily reflects severe hepatic insulin resistance with failure to suppress nocturnal hepatic glucose production.
• IGT ($2\text{h OGTT } 140\text{–}199\text{ mg/dL}$) primarily reflects peripheral (skeletal muscle) insulin resistance and impaired early-phase insulin release.
• Patients with both IFG and IGT carry approximately twice the annual risk of progression to overt diabetes compared to either defect alone.

1. Drugs Elevating Plasma Glucose: Systemic corticosteroids (dexamethasone, prednisone), calcineurin inhibitors (tacrolimus, cyclosporine), atypical antipsychotics (olanzapine, clozapine), thiazide diuretics, protease inhibitors, immune checkpoint inhibitors (anti-PD-1 induced rapid autoimmune diabetes).
2. Drugs Falsely Lowering $HbA_{1c}$: Dapsone (induces subclinical hemolytic anemia), ribavirin, high-dose vitamin C and vitamin E (antioxidant inhibition of hemoglobin glycation), erythropoiesis-stimulating agents (darbepoetin, epoetin).
3. Assay Interferences by Hemoglobin Variants: Hemoglobin variants (HbS, HbC, HbE, HbD) and elevated fetal hemoglobin (HbF > 10%) can cause analytical interference on certain older cation-exchange HPLC instruments. Modern boronate affinity chromatography and immunoassay methods measure total glycated hemoglobin without interference from common heterozygous variants (HbAS, HbAC).

• Falsely LOW $HbA_{1c}$ in Altered Red Cell Kinetics:
• Hemolytic anemias (hereditary spherocytosis, AIHA, G6PD deficiency).
• Chronic kidney disease on hemodialysis (reduced RBC lifespan + erythropoietin).
• Recovery from acute blood loss or recent red blood cell transfusion.
• Second and third trimesters of pregnancy (hemodilution + increased red cell turnover).
• Falsely HIGH $HbA_{1c}$ in Nutritional Deficiencies:
• Severe Iron Deficiency Anemia: Red cell production drops, resulting in an older average circulating red cell population with prolonged glucose contact time. Treating with iron normalizes HbA₁c independent of glycemia!
• Vitamin B₁₂ and folate deficiency.
• Post-splenectomy (delayed clearance of aged erythrocytes).

> [!CAUTION] > Urgent Evaluation for Diabetic Emergencies: > 1. Random Glucose $> 300\text{ mg/dL}$ ($> 16.7\text{ mmol/L}$) with Nausea/Vomiting/Abdominal Pain: Immediate evaluation for Diabetic Ketoacidosis (DKA); check serum beta-hydroxybutyrate, arterial/venous blood gas, and serum electrolytes with anion gap! > 2. Profound Hyperglycemia ($> 600\text{ mg/dL}$ / $> 33.3\text{ mmol/L}$) with Altered Mental Status: Suggests Hyperosmolar Hyperglycemic State (HHS); calculate effective serum osmolality (> 320 mOsm/kg). > 3. Documented Plasma Glucose $< 54\text{ mg/dL}$ ($< 3.0\text{ mmol/L}$): Serious neuroglycopenic hypoglycemia; requires immediate oral fast-acting carbohydrate or parenteral dextrose / IM glucagon.

• Estimated Average Glucose (eAG) Formula:

$eAG (mg/dL) = 28.7 × HbA₁c - 46.7$

• HbA₁c 6.0% ≈ 126 mg/dL
• HbA₁c 7.0% ≈ 154 mg/dL
• HbA₁c 8.0% ≈ 183 mg/dL
• HbA₁c 9.0% ≈ 212 mg/dL
• Fructosamine as an Alternative: Reflects glycation of serum proteins (predominantly albumin). Useful when HbA₁c is invalid (hemoglobinopathies, hemolysis, pregnancy); reflects glycemic control over the preceding 2 to 3 weeks.
• ADA General Glycemic Target: For most non-pregnant adults with diabetes, the recommended target is HbA₁c < 7.0% (< 53 mmol/mol) or Time in Range (70–180 mg/dL) > 70% on CGM. More relaxed targets (< 8.0%) are appropriate in patients with extensive comorbidities or limited life expectancy.

• Serum Electrolytes: Calculates the serum anion gap (Na⁺ - [Cl⁻ + HCO₃⁻]) in DKA and assesses hypokalemia risk prior to starting insulin.
• Renal Function Tests & eGFR: Identifies diabetic nephropathy and determines dosing safety for metformin (contraindicated if eGFR < 30 mL/min/1.73 m²) and SGLT2 inhibitors.
• Urine Protein / Albumin-to-Creatinine Ratio (ACR): Primary screening test for diabetic microvascular kidney injury (ACR ≥ 30 mg/g).
• Lipid Profile: Assesses atherogenic dyslipidemia (elevated triglycerides, low HDL, elevated small dense LDL particles) universally linked to insulin resistance.